OOIR: Observatory of International Research

Papers

(The TQCC of ESMO Open is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Editorial Board	248
Editorial Board	220
87P Characteristics and outcomes of 11 patients with myoepithelial tumors: The Gustave Roussy experience	144
94P Efficacy of first-line pembrolizumab in elderly patients with advanced non-small cell lung cancer with high PD-L1 expression	141
Letter comments on: Drug–drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of patients with metastatic breast cancer	134
PP289 Potential anti-tumour therapy in nasopharyngeal carcinoma: MDM2 siRNA-based approaches	128
OP01-2 Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors	124
107P Clinicopathologic features of breast cancer patients in a single tertiary hospital in the Philippines	108
284P Risk assessment for systemic recurrence in HER2-low breast cancer: Evaluating hormone receptors and immunohistochemical profiles	104
258P Real-world (rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherap	104
266O Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer: Results from an international cohort study	101
ESMO	98
70P Development and validation of a machine learning (ML) nomogram to predict RSClin results and guide adjuvant treatment of node-negative (N0) hormone receptor-positive (HR+)/human epidermal growth f	92
70P Invasive lobular breast cancer (ILC), an overlooked subtype in clinical trials	89
103P Impact of Prosigna test on treatment decision in lymph node-negative early breast cancer: A prospective multicenter study (EMIT1)	89
PP018 PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling	88
118P Real-world treatment patterns and clinical outcomes among high risk, early stage HER2-negative breast cancer (BC) patients in Alberta, Canada	87
200P OlympiAD: Exploratory analysis of olaparib vs capecitabine in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (mBC)	87
267P Ultrasound-guided injection with or without rehabilitation exercise in breast cancer survivors with subacromial-deltoid bursitis: Long-term results of a pilot randomized clinical study	84
OP27 A phase II study of neoadjuvant erlotinib for operable stage II or IIIA non-small cell lung cancer with epidermal growth factor receptor activating mutations	80
Editorial Board	78
47P Sarcoma in the Czech Republic: Update data through 2021 including epidemiology, patients flow and treatment outcomes	75
51O The European Prospective Investigation into Cancer and nutrition cohort (EPIC): A gateway to rare cancer epidemiological research – Insights from the EPIC Rare Cancers Working Group	69
107P The actin cytoskeleton as a new target structure for metastasizing osteosarcoma	68
62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutatio	68

PP049 Redistribution of 8-oxo-G/AP sites hot spots mediated transcription alteration is a novel and ubiquitous mechanism in EGFR-TKI resistance of NSCLC	68
8P Clinicopathological features and the role of adjuvant therapy in the management of gastrointestinal verrucous carcinoma	67
Editorial Board	67
10P The risk of second primary lymphoma in colorectal cancer: An updated SEER analysis 2000–2020	67
97P Cost-effectiveness of TTFields in addition to standard systemic therapy for stage IV non-small cell lung cancer patients following progression on or after platinum-based chemotherapy	65
129P FDG PET imaging of symptomatic chest wall myositis following stereotactic body radiation therapy (SBRT) for patients with early stage cell lung cancer	64
128P Innovative limb salvage: Liquid nitrogen approach in reconstruction after bone tumor resection	58
55P The SOS inhibitor BAY293 contributes to amplified vertical inhibition of the MAP kinase pathway in human melanoma cells	56
146P The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis	54
148P Identification of potential predictive biomarkers for ovarian cancer chemotherapy response	54
83P Cost-effectiveness analysis of talazoparib maintenance treatment for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US	53
57P Two cases of adult rhabdomyosarcoma of the head and neck successfully treated with pazopanib	53
180P Improving the referral pathway for breast cancer patients: Lessons learnt from 1-year pilot	52
174P Endocrine disruptors and life STILe in patients carrying BRCA pathogenic VAriants with breast and/or ovarian CAncer and women without neoplasm: The STILVARCA study	52
63P Redefining the role of CA 19-9 as a prognostic marker in epithelial ovarian cancer	51
68P Prognosis of ovarian cancer patients with the Mexican founder mutation (a BRCA1 long genomic rearrangement) compared with other BRCA1/2 mutations	50
232P Real-world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom	49
39P A validation study of a self-testing capillary kit, the rhelise kit for therapeutic dose monitoring (TDM) of tamoxifen, Z-endoxifen, and 4-hydroxytamoxifen in breast cancer patients	49
22P Emerging role of histone acetyltransferase CBP in breast cancer cells undergoing DNA damage	48
37P Dose transition pathways for time-to-event continual reassessment method (TITE-CRM): Will imposing a waiting time result in better performance?	48
63P Activity and safety of FGFR inhibitors in pan-cancer patients with FGF/FGFR alterations and advanced malignancies: A pooled analysis of 7 phase I/II trials	48
175P Quality of life in patients with NSCLC brain metastases undergoing different local therapies in the era of precision oncology: A territory-wide study	47
140P Use of chemotherapy and loco-regional therapy for stage IA triple-negative breast cancer and their association with oncologic outcomes: A cancer registry study	47
74P Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis	47
164P Circulating cytokines levels as predictive biomarkers in pleural mesothelioma: Preliminary data from a prospective translational study	47
PP175 Unexpected high frequency of pathogenic germline variant (rs34804482, NM_018490.3: c.2531A>G) of the LGR4 gene in Tuvan ethnic group from West Siberia	46
35P Genomic and clinical landscape of metastatic hormone receptor-positive breast cancers carrying ESR1 alterations	46
PP002 Unravelling the effects of bisphenol A on colorectal cancer progression in obese Sprague-Dawley rats	46
130P Progesterone receptor (P) status and survival outcomes of ER-negative breast cancer: A population-based cohort study	46
PP153 A randomized, open-label phase ii study comparing a novel regimen of dose-dense docetaxel-cyclophosphamide alternating with epirubicin-cisplatin against anthracycline-taxane in early TNBC, strat	45
PP075 Xia Yuxue decoction inhibits hepatocellular carcinoma metastasis by reducing the abundance of the tumor-resident bacterium Brachybacterium sp.	45
Table of Contents	44
143P Post-recurrence treatment in modern adjuvant or neoadjuvant soft-tissue sarcoma randomized trials: A cross-sectional study of published trials between 2015 and 2024	43
Table of Contents	43
Corrigendum to “Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients	43
115P Impact of clinical and treatment factors on trabectedin toxicity in soft tissue sarcomas	43
50P Combination of platinum-based chemotherapy with immunotherapy in treatment of extrapulmonary neuroendocrine carcinoma: A retrospective study	42
76P Relative dose-intensity of trabectedin and outcome of advanced L-sarcomas	42
Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX	42
2O Prostate cancer BRCA mutation prediction using multiple-instance learning and histopathology	41
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results	41
137P PHANTOM: Bootstrap inference of single-cell tumour phylogenies by integrating sequencing read counts	41
Table of Contents	40
6P An innovative evidence-based laboratory medicine (EBLM) test to help doctors in the screening of ovarian cancer	38
142P The predictive value of progesterone receptor expression on pCR following neoadjuvant chemotherapy in breast cancer	37
Oncology professionals’ perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series	37
144P TRIple-negative breast cancer PrOspective registry in MiddLe East AfrIca (TRIPOLI) study: Interim analysis of treatment outcomes in patients who received neoadjuvant therapy	37
217P Switching cyclin-dependent kinase inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/human epidermal growth factor-negative (HER2-) advanced breast cancer (ABC) who experienced	37
97P Drug sensitivity prediction based on RNA expression profiling in colorectal cancer organoids	37
Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer	37

Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities	36
225P Impact of cyclin inhibitors (CDK4/6i) on immune cell populations in first-line treated metastatic breast cancer (mBC) patients	36
PP474 Isoliensinine enhances therapeutic efficacy of paclitaxel and induces mitochondria-mediated cell death in multidrug-resistant colon cancer stem cells	36
338P Real-world progression-free survival (PFS) and overall survival (OS) for advanced breast cancer (aBC) treated with ribociclib (RIB) in the RIBANNA trial	35
Response to: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)	35
27O First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors validates PARP7 as a novel anticancer therapeutic target	35
103P MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience	35
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopaus	35
Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)	34
Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial	34
Systemic anticancer therapy near the end of life: an analysis of factors influencing treatment in advanced cancer patients	34
199P Radiomics analysis predicts chemoimmunotherapy advantage over chemotherapy alone in extensive-stage small cell lung cancer (ES SCLC)	33
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study	33
Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study	33
90P Effect of atirmociclib plus endocrine therapy (ET) on serum thymidine kinase activity (TKa) in a phase I study of patients with HR+/HER2− metastatic breast cancer (mBC)	33
71P Relapse rate in patients avoiding adjuvant chemotherapy based on Oncotype DX score: Real-world data from three UK centres	32
211P Risk of recurrence (ROR) among patients (pts) with HR+/HER2− early breast cancer (EBC) involving 1-3 axillary lymph nodes (N1): A real-world evaluation	31
393P Treatment outcomes and toxicity of palbociclib in metastatic hormone receptor (HR)-positive HER2 -ve breast cancer patients: Real-life palbociclib outcome in Omani patients	31
Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies	31
307P Relationship between physician-graded symptomatic adverse events and patient-reported quality of life (QOL): An analysis of the phase III PALLAS trial	31
148P AI driven adjuvant therapy: Predicting pCR from radiological data in patients receiving incomplete NACT for LABC	31
412TiP HEROES: De-escalation of medical therapies in HER2-positive metastatic breast cancer in long-term persistent response and minimal residual disease undetectable in circulating tumor DNA	31
357P BRCA genetic testing implementation and the impact of BRCA pathogenic variant status on clinical outcomes in HER2-negative metastatic and recurrent breast cancer in Japan	30
225P The impact of predictive genomic testing in Ireland: Financial and resource implications for healthcare institutions and patients	30
334P The nationwide Advanced Breast Cancer - Patient Care Initiative (ABC-PCI): A medical oncologist-led survey on quality of life in Chinese patients with metastatic triple-negative breast cancer	30
420P Physicians’ knowledge, practice and attitudes on fertility and pregnancy-related issues in young women with advanced breast cancer: Results of the ABC6 and ABC7 survey	30
238P Comparing the benefit-risk profiles of emerging treatments in early breast cancer (eBC) using the ESMO MCBS and the ASCO value framework	30
43eP Is age a risk factor for locally advanced cervical cancer persistence?	29
An innovative model of delivering cancer care in the community: the experience of a tertiary cancer centre in Singapore	29
152P Pregnancy after gestational trophoblastic neoplasia: Navigating fertility post-chemotherapy	29
Phase I PIANO trial—PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes	29
438P Antidepressants/anxiolytics and breast cancer treatment: The case of drug-drug interactions	29
222P Hemoglobin A1c screening for patients with early breast cancer treated with adjuvant endocrine therapy	29
38P Real-world treatment patterns and effectiveness of subsequent treatments following first-line (1L) brigatinib for patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cance	29
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer	28
16eP Efficacy and safety of bevacizumab biosimilar in the treatment of brain metastases from breast cancer: A prospective, single-arm, multicentre, real-world study	28
Utilizing phenotypic characteristics of metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: developme	28
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers	28
83P Efficacy and safety of KRAS G12C inhibitors across solid tumors: A systematic review and meta-analysis	28
48P An AI System for accurate Ki-67 IHC assessment in breast cancer following the IKWG whole section global scoring protocol	28
22P PillPal.ai: Using artificial intelligence to improve adherence to oral chemotherapy, TKIs, and CDK4/6 Inhibitors - A pilot study from a tertiary cancer centre in India	28
Total pain, opioids, and immune checkpoint inhibitors in the survival of patients with cancer	27
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cance	27
Worldwide cancer statistics of adolescents and young adults in 2019: a systematic analysis of the Global Burden of Disease Study 2019	26
185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the rando	26
Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial	26
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study	26
SWI/SNF family mutations in advanced NSCLC: genetic characteristics and immune checkpoint inhibitors’ therapeutic implication	26
Concurrent antibody–drug conjugates and radiotherapy: a new perspective on radiation necrosis in HER2-positive breast cancer brain metastases from the DESTINY-Breast03 and HER2CLIMB trials	25
Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review	25
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]	25
Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe	25
Refining patient selection for breast cancer immunotherapy: beyond PD-L1	25
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting	25
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single	25
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMAN	25
72MO Homologous recombination deficiency (HRD) and genomic subgroup analysis in patients (pts) with platinum-sensitive ovarian cancer (PSOC) receiving mirvetuximab soravtansine-gynx (MIRV) in the PICC	25
100P Combinatorial treatment strategies for overcoming the immunotherapy resistance in soft tissue sarcomas	25
Psychiatric disorders in adolescent and young adult cancer survivors in Korea	24
Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets	24
23P Anti-tumor activity of novel Globo-H targeting CAR T cells in cholangiocarcinoma model	24
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)	24
108P Biomarkers and personalized cancer therapy: A study of trial discontinuation and unpublished rates	24
Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers	24
Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study	23
Cholangiocarcinoma patients with FGFR2 fusions/rearrangements but primary refractory to pemigatinib: the real challenge?	23
Comments on ‘Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer’	23
131P Symptoms, fear of cancer recurrence and supportive care needs in gastrointestinal stromal tumor patients undergoing targeted therapy	23
Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis	23
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A	23
52P Liquid biopsy monitoring in BRAF V600E mutated NSCLC patients treated with dabrafenib plus trametinib: A prospective, explorative, multicentric study, LiBRA study (GOIRC-03-2020)	23
Collagen signature adds prognostically significant information to staging for breast cancer	23
Determining fitness for enfortumab vedotin and pembrolizumab in metastatic bladder cancer: the time to move beyond isolated comorbidity assessments	23
6P vAO - Variant Annotator for OncoKB: A simplified interface to identify targeted therapies for somatic tumors	23
The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients—a multicenter real-world analysis	22
Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes	22
Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis	22
268MO Safety of vaginal estrogen therapy after early-stage breast cancer: A nationwide population-based target trial emulation	22
33P Antitumor activity of TROP2 antibody drug conjugate datopotamab deruxtecan in chemotherapy-resistant breast cancer models	21
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer	21

Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer	21
Cancer-related fatigue and depression: a monocentric, prospective, cross-sectional study in advanced solid tumors	20
108P Unravelling how different treatment sequences affect survival in osteosarcoma patients: A population-based study	20
21P Squamous cell carcinoma arising from germ cell tumour of the ovary treated with immunotherapy	20
14P Unravelling the immune landscape of non-epithelial ovarian cancer	20
Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs	20
205P VERITAC update: Phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer	20
44P Reintroduction of platinum-based chemotherapy ± mitotane for advanced adrenocortical cancer: Single-center retrospective trial	20
45P Integrative analysis of TCGA DNA methylation, RNA-sequencing, and variant dataset using machine learning in predicting endometrial cancer recurrence	20
11P Conization before radical hysterectomy in early cervical cancer: A Korean multi-center study	20
7P Unveiling the prognostic significance of protein expression in advanced high-grade serous ovarian cancer: A comparative study between long-term survivors and early mortal patients	20
59P Delay in diagnosis of soft tissue sarcoma (STS): Contributing factors and their impact on overall survival - Experience from a tertiary care hospital	20
89P Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients	20
17P Exploiting the immune-modulatory effects of PI3K/mTOR inhibitors to enhance response to immune-checkpoint blockade in uterine leiomyosarcoma	20
53P Characterization of the non-ATP competitive PI3Kdelta inhibitor IOA-244 in lymphoma models: From single agent to combination screen and clinical investigation	19
73P TROP2 amplification is highly present in dedifferentiated liposarcoma: Data from the Cancer Genome Atlas (TCGA) in soft tissue sarcoma	19
132P Novel small molecule modulators for activation of mutant tumor suppressor p53	19
29P First-line of camrelizumab, apatinib mesylate and chemotherapy for advanced high-grade neuroendocrine tumors (NETS): A single center, single arm, exploratory study	19
94P Clinical utility of long read sequencing for comprehensive analysis of cancer patient genomes	19
117P Merkel cell carcinoma: Epidemiological pattern in the United States, a SEER based study	19
Corrigendum to ‘A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-	19
Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study	19
272P Evaluating a digital tool for supporting people affected by breast cancer: A prospective randomised controlled trial - The ADAPT study	18
224P Efficacy of single-agent second-line fulvestrant (FUL) in metastatic invasive lobular carcinoma (mILC) exposed to first-line aromatase inhibitors (AI) and cyclin-dependent kinase 4 and 6 inhibito	18
233P Real-world first-line (1L) treatment selection for Australian patients (pts) with hormone receptor-positive advanced breast cancer (HR+ ABC)	18
208P The discrepancies between real-world evidence and clinical trials: A study investigating stage IV SCLC	18
153P Discovery of new BRCA1/2 mutations not described in the international breast consortium	18
46P The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis	18
54P Comparison of ctDNA profiles in lobular vs NST hormone receptor-positive metastatic breast cancer patients in early lines of treatment	18
296P Management of sexual dysfunction in breast cancer survivor women on adjuvant therapy	18
297P Modified Delphi consensus on interventions for radiation dermatitis in breast cancer: A Canadian expert perspective	18
83P Radiological evaluation of response in patients with soft tissue sarcoma treated with trabectedin	18
154P Alternative splicing in non-small cell lung cancer evolution	18
142P Exploring 18F-FDG PET as a predictior of immune-related adverse events (irAEs) in early-stage triple-negative breast cancer (eTNBC)	18
Editorial Board	18
93P Intra- and post-operative management of sentinel lymph node micrometastasis and prognosis analysis in patients with breast cancer from southern China: A multicenter, retrospective, real-world stud	18
147P Population-adjusted indirect comparisons of repotrectinib and entrectinib in ROS1+ locally advanced or metastatic non-small cell lung cancer (NSCLC)	18
243P Identifying the communication needs of people living with metastatic breast cancer (MBC) in Ireland: An all-Ireland patient-led survey (CTRIAL-IE 23-05)	18
152P Nanopore sequencing of cfDNA captures key copy number alterations in lung adenocarcinoma: A non-invasive approach for prognosis, therapy, and subtyping	18
54P Efficacy of first-line immunotherapy for non-small cell lung cancer with MET exon 14 skipping according to PD-L1 expression	17
252P Characterization of sexual dysfunction in women with lung cancer: Update of the CLARIFY project	17
18P AURKB inhibition radiosensitises NSCLC by altering mitotic fate	17
90P Is physician-patient language concordance better for clinical trial enrollment in breast cancer patients? A real-life study	17
PP108 Is it possible to avoid seroma after mastectomy and axillary lymph node dissection using microporous polysaccharide hemispheres (AristaTM)?	17
16P A phase Ib/II trial to evaluate safety and efficacy of aurora kinase inhibitor LY3295668 in combination with osimertinib for patients with EGFR-mutant non-small cell lung cancer	17
139P Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: A systematic review and network meta-analysis	17
108P Establishing a multi-modal tissue preparation and imaging workflow to study heterogeneity in neuroblastoma tumors	17
PP067 Predicting tolerability of high-dose fentanyl buccal tablets in cancer patients	17
OP28 Cost-effectiveness analyses of durvalumab consolidation therapy compared to no consolidation therapy after definitive chemoradiotherapy in stage III NSCLC	17
96P Age-adjusted trends and survival analysis of alveolar soft part sarcoma	17
17P Efficacy and safety of furmonertinib as salvage treatment for EGFR-mutated NSCLC patients progressed on third-generation EGFR TKIs	17
161P DESCARTES trial: De-ESCAlating RadioTherapy in patients with pathologic complete response to neoadjuvant systemic therapy	17
18P PARP1 trapping and hyperactivation by the decoy agonist OX425 induces DNA repair abrogation and a robust anti-tumor immune response	17
263P Cross-sectional nationwide population-based study of living conditions, and identification of sexual and fertility profiles among young women after breast cancer in France: A study of the French	17
PP215 Differential efficacy of tyrosine kinase inhibitors (TKIs) according to the type of EGFR activating mutations and agents in non-small cell lung cancer (NSCLC): A real-world study	17
14P Comparison of single-cell ERBB2 mRNA expression levels with HER2 status by immunohistochemistry reveals heterogeneity of the HER2-low status	16
79P Real-world comparative analysis of liposomal doxorubicin and paclitaxel in first-line treatment of Kaposi sarcoma: A retrospective study in Brazil	16
76P Circadian control of neutrophil extracellular trap formation temporally regulates metastatic lung cancer progression	16
Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study)	16
58P The lymphocyte activation gene-3 (LAG-3) protein expression in tumor-infiltrating lymphocytes is associated with a poor prognosis of ovarian clear cell carcinoma	16
PP065 In silico genetic polymorphisms analysis of GSTP1 and their effect on platinum compound and antituberculosis drugs co-medication in lung cancer patients with tuberculosis comorbidity	16
PP499 3-weekly daratumumab-based quadruplet induction regimen is highly effective in newly diagnosed multiple myeloma	16
153P BRAF variants and therapy outcomes in melanoma	16
The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanoma	16
5MO Effect of amivantamab dose interruptions on efficacy and safety of first-line amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: Exploratory analyses from the MARIPOSA study	16
80P Efficacy, FDA approval, innovativeness, clinical evidence, and price of breast, ovarian, endometrial, and cervical cancer drugs	16
PP064 MicroRNA 200c-3p targeting CDH1 gene polymorphism towards risk susceptibility of prostate cancer in North Indian population	16
142P Role and impact of hypoxia-inducible factor 1-alpha on survival rates in pancreatic cancer: A systematic review and meta-analysis	16
58P Evaluating the impact of WGTS in routine diagnostics of bone and soft tissue tumors	16
Extravasation associated with cancer drug therapy: multidisciplinary guideline of the Japanese Society of Cancer Nursing, Japanese Society of Medical Oncology, and Japanese Society of Pharmaceutical O	16
258TiP A phase II trial of loperamide (L) and granulocyte colony-stimulating factors (G-CSF) to improve sacituzumab govitecan (SG) tolerance in patients (pts) with unresectable locally advanced or met	16
53P Tumor-agnostic detection and monitoring of circulating tumor DNA in HER2-positive early-stage breast cancer	15
Promoting large multinational academic clinical trials for gastrointestinal cancers in Europe: the ENGIC (European Network for GI Cancers) initiative	15
77P The impact of COVID-19 on gynecological cancer diagnoses in Greece	15
136P Vascular endothelial growth factor A (VEGF-A) expressions in invasive breast cancer and its association with lymph node metastasis and histopathologic features	15
120P Genetic associations of plasma proteins and breast cancer: Potential therapeutic drug candidates	15
74P Evaluation of the clinical significance of rare epidermal growth factor receptor exon 19 insertion-deletion variants on tyrosine kinase inhibitor efficacy in non-small cell lung cancer: A five-yea	15
65eP Real-world impact of pembrolizumab plus lenvatinib in metastatic uveal melanoma: A retrospective multicenter study	15
30P Novel integrated tumor micro-/macro-environment (TMME) subtypes for prediction of treatment response to neoadjuvant anti-HER2 therapy	15
189O Ribociclib + endocrine treatment vs SoC chemotherapy in intermediate risk HR+/HER2- early breast cancer: Results from the neoadjuvant cohort of the phase-III WSG ADAPTcycle – trial	15
273P Clinicopathological features and outcomes in patients with BRCA-associated HR+/HER2- breast cancers eligible for adjuvant CDK4/6 and PARP inhibitors	15
124P Melittin inhibits the growth of hepatocellular carcinoma Huh7 cells by downregulating LARS2 and ZNF19	15
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers	15
178P Comparative study between wise pattern and non-vertical scar reduction mammoplasty	15
134P Gene alterations in Mongolian breast cancer patients	15
56P Neoadjuvant treatment with sequential letrozole and exemestane in postmenopausal patients with HR-positive, HER-2 negative breast cancer: Clinical and biomarker outcomes from the NEOLETEXE trial	15
246P Four years of Oncotype DX test in clinical practice: the experience of the breast unit of University Hospital of Parma	14
398P Evaluation of trastuzumab deruxtecan for metastatic HER2+ breast cancer: A meta-analysis	14
37eP Local control with chemoradiotherapy in patients with metastatic cervical cancer	14
220P Efficacy and saftey of neoadjuvant trastuzumab, pyrotinib and chemotherapy in HER2-positive breast cancer: A real-world study	14
24P The role of radiotherapy for intermediate-risk in early-stage cervical cancer post-radical hysterectomy: A meta-analysis	14
Association between DNA damage repair alterations and outcomes to 177Lu-PSMA-617 in advanced prostate cancer	14
430P Analysis of quality of life in a group of very long-term early stage breast cancer survivors	14
85P Niraparib customized dosing regimen (RADAR) to manage thrombocytopenia events in platinum-sensitive recurrent ovarian cancer patients: The NEWTON trial	14
229P Risk of recurrence and overall survival in Stage II and III ER+/HER2- early breast cancer: A population-based registry study in Sweden	14